Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
ORGANIZATION
JPMA Launches New Legal Entity, Set for October Transition
The Japan Pharmaceutical Manufacturers Association (JPMA) on May 1 formally established a general incorporated association as part of its transition from a voluntary organization, with a full shift scheduled for October. The move coincides with the anniversary of the group’s…
To read the full story
Related Article
- JPMA to Complete Shift to Legal Entity on October 1
September 30, 2026
- JPMA Reshaping Organization to Boost Agility as It Shifts to Legal Entity
April 16, 2026
ORGANIZATION
- PhRMA Sues CMS over Medicare MFN Model, Calls It Unlawful Overreach
October 9, 2026
- Japan Generic Group Calls for Clearer Patent Extension Rules
October 9, 2026
- 3 Pharma Groups Press Government to Rethink CEA Expansion
October 8, 2026
- JPMA Chief Urges Manufacturing, Talent Push to Build Drug Discovery Ecosystem
October 8, 2026
- PhRMA Taps Jonathan Kushner as New Japan Representative
October 6, 2026
Japan’s plasma-derived product industry is approaching a turning point as the government prepares to step in with unprecedented support for…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…